Table 4.
ORs and 95% CIs of prostate cancer according to plasma level of lipid-adjusted organochlorines by stage.
| Quartile category |
|||||
|---|---|---|---|---|---|
| Organochlorine | Low | Second | Third | High | p for trend |
| Localized | |||||
| o,p′-DDT | |||||
| Cases/controls | 25/66 | 41/70 | 44/70 | 29/72 | |
| ORa (95% CI) | 1.00 | 1.79 (0.88–3.65) | 2.01 (0.96–4.22) | 1.17 (0.50–2.74) | 0.59 |
| p,p′-DDT | |||||
| Cases/controls | 30/65 | 46/71 | 37/71 | 26/71 | |
| ORa (95% CI) | 1.00 | 1.35 (0.71–2.55) | 0.97 (0.49–1.93) | 0.65 (0.29–1.46) | 0.12 |
| p,p-DDE | |||||
| Cases/controls | 35/67 | 34/70 | 48/70 | 22/71 | |
| ORa (95% CI) | 1.00 | 0.86 (0.47–1.59) | 1.33 (0.72–2.45) | 0.56 (0.27–1.15) | 0.14 |
| trans-Nonachlor | |||||
| Cases/controls | 35/67 | 42/67 | 28/75 | 34/69 | |
| ORa (95% CI) | 1.00 | 1.18 (0.65–2.14) | 0.57 (0.26–1.25) | 0.74 (0.29–1.90) | 0.65 |
| cis-Nonachlor | |||||
| Cases/controls | 35/69 | 37/61 | 34/77 | 33/71 | |
| ORa (95% CI) | 1.00 | 1.22 (0.67–2.24) | 0.82 (0.42–1.61) | 0.86 (0.38–1.95) | 0.65 |
| Oxychlordane | |||||
| Cases/controls | 31/63 | 48/74 | 26/71 | 34/70 | |
| ORa (95% CI) | 1.00 | 1.19 (0.62–2.30) | 0.70 (0.33–1.46) | 0.80 (0.30–2.10) | 0.53 |
| HCB | |||||
| Cases/controls | 36/66 | 29/70 | 43/71 | 31/71 | |
| ORa (95% CI) | 1.00 | 0.72 (0.28–1.87) | 0.97 (0.37–2.53) | 0.73 (0.26–2.06) | 0.64 |
| Mirex | |||||
| Cases/controls | 33/67 | 29/66 | 44/77 | 33/68 | |
| ORa (95% CI) | 1.00 | 0.90 (0.45–1.81) | 1.21 (0.63–2.32) | 1.27 (0.58–2.78) | 0.44 |
| β-HCH | |||||
| Cases/controls | 35/63 | 32/69 | 42/75 | 30/71 | |
| ORa (95% CI) | 1.00 | 0.85 (0.44–1.63) | 1.10 (0.59–2.06) | 0.69 (0.34–1.37) | 0.33 |
| ∑PCBs | |||||
| Cases/controls | 41/88 | 33/64 | 35/63 | 30/63 | |
| ORa (95% CI) | 1.00 | 1.24 (0.66–2.34) | 1.33 (0.71–2.50) | 1.32 (0.59–2.96) | 0.59 |
| Advanced | |||||
| o,p′-DDT | |||||
| Cases/controls | 10/24 | 12/25 | 11/23 | 11/23 | |
| ORa (95% CI) | 1.00 | 0.81 (0.25–2.63) | 0.75 (0.18–3.18) | 0.96 (0.22–4.26) | 0.93 |
| p,p′-DDT | |||||
| Cases/controls | 8/21 | 12/26 | 15/23 | 9/25 | |
| ORa (95% CI) | 1.00 | 0.99 (0.27–3.69) | 1.42 (0.34–5.99) | 0.61 (0.11–3.38) | 0.55 |
| p,p′-DDE | |||||
| Cases/controls | 13/23 | 11/24 | 5/21 | 15/27 | |
| ORa (95% CI) | 1.00 | 0.98 (0.29–3.36) | 0.23 (0.05–1.18) | 0.69 (0.19–2.55) | 0.64 |
| trans-Nonachlor | |||||
| Cases/controls | 10/23 | 11/24 | 9/22 | 14/26 | |
| ORa (95% CI) | 1.00 | 1.12 (0.31–4.10) | 1.19 (0.29–4.88) | 2.46 (0.44–13.73) | 0.28 |
| cis-Nonachlor | |||||
| Cases/controls | 13/24 | 7/20 | 10/27 | 14/24 | |
| ORa (95% CI) | 1.00 | 0.48 (0.12–1.85) | 0.71 (0.21–2.39) | 1.55 (0.34–7.11) | 0.43 |
| Oxychlordane | |||||
| Cases/controls | 12/23 | 11/24 | 13/24 | 8/24 | |
| ORa (95% CI) | 1.00 | 0.50 (0.13–2.01) | 0.78 (0.19–3.27) | 0.31 (0.04–2.54) | 0.38 |
| HCB | |||||
| Cases/controls | 10/24 | 11/22 | 10/25 | 13/24 | |
| ORa (95% CI) | 1.00 | 1.13 (0.24–5.21) | 0.53 (0.11–2.43) | 0.78 (0.10–6.10) | 0.90 |
| Mirex | |||||
| Cases/controls | 14/21 | 8/27 | 7/24 | 15/23 | |
| ORa (95% CI) | 1.00 | 0.38 (0.10–1.46) | 0.38 (0.10–1.49) | 1.60 (0.35–7.23) | 0.26 |
| β-HCH | |||||
| Cases/controls | 12/23 | 14/24 | 7/24 | 11/24 | |
| ORa (95% CI) | 1.00 | 0.64 (0.19–2.12) | 0.35 (0.07–1.69) | 0.31 (0.07–1.45) | 0.23 |
| ∑PCBs | |||||
| Cases/controls | 18/27 | 9/23 | 6/22 | 11/23 | |
| ORa (95% CI) | 1.00 | 0.36 (0.09–1.49) | 0.18 (0.04–0.92) | 0.32 (0.06–1.61) | 0.17 |
a
Adjusted for smoking status, alcohol intake, marital status, body mass index, and intake of green tea and miso soup.
Adjusted ORs were calculated based on subjects with complete information on covariates.